SNOWDROP TRIAL23 | Findings |
Naturally postmenopausal women with HSDD (n = 481 Placebo, n = 468 flibanserin 100 mg HS) for 24 weeks. | Mean (SE) change from baseline in FSFI score Placebo: 0.4 (0.1) flibanserin100 mg HS: 0.7 (0.1), P < 0.001 Mean (SE) change from baseline in SSEs Placebo: 0.6 (0.1) flibanserin100 mg HS: 1.0 (0.1), P = 0.004 Most common AEs: dizziness (9.9%), somnolence (8.8%), nausea (7.5%); discontinuation due to AEs: 8.1% of flibanserin treated patients |